ORIC Stock Analysis: Buy, Sell, or Hold?
ORIC - Oric Pharmaceuticals, Inc. Common Stock
$8.91
-0.02 (-0.22%)
▼
5d:
+6.07%
30d:
+5.32%
90d:
-19.95%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Smart Money Accumulation
None View Scanner →
Strength: 4.2/10
Get Alerted When ORIC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ORIC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ORIC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ORIC is currently trading at $8.91, which is considered extended relative to its 30-day fair value range of $7.81 to $8.61.
Technical Outlook: Technically, ORIC is in a strong downtrend. The price is approaching resistance at $9.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ORIC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.29 (+127.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ORIC is in a strong downtrend. The price is approaching resistance at $9.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ORIC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.29 (+127.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.81 -
$8.61
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 127.7% below Wall St target ($20.29)
Trading Range Analysis
30-Day Trading Range
$7.81 -
$8.61
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.45
Resistance Level
$9.16
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.66
Wall Street Target
$20.29
(+127.7%)
Share & Embed Analysis
Last updated: June 23, 2026 9:04 PM ET
Data refreshes hourly during market hours. Next update: 10:04 PM
Data refreshes hourly during market hours. Next update: 10:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORIC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Dominic Piscitelli
SELL
52000 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 67 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
